Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1201747 | 1.00 | PTPN1 (0.63) | PTPN1ESR2HDAC8NR1H2NR1H3 | |
| SCHEMBL2895743 | 0.95 | PTPN1 (0.69) | PTPN1ESR2HDAC8 | |
| SCHEMBL29369360 | 0.95 | PTPN1 (0.69) | PTPN1ESR2HDAC8 | |
| SCHEMBL1202386 | 0.95 | PTPN1 (0.69) | PTPN1ESR2HDAC8 | |
| SCHEMBL30592013 | 0.95 | PTPN1 (0.69) | PTPN1ESR2HDAC8 | |
| SCHEMBL17486413 | 0.95 | PTPN1 (0.69) | PTPN1ESR2HDAC8 | |
| SCHEMBL16196415 | 0.89 | PTPN1 (0.62) | PTPN1ESR2HDAC8NR1H2NR1H3 | |
| SCHEMBL16196419 | 0.89 | PTPN1 (0.62) | PTPN1ESR2HDAC8NR1H2NR1H3 | |
| SCHEMBL546157 | 0.88 | ESR2 (0.56) | PTPN1ESR2HDAC8 | |
| SCHEMBL2078707 | 0.87 | ESR2 (0.51) | PTPN1ESR2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045266-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | PTPN1 3493/4885ESR2 3267/4885HDAC8 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.